Zoetis Inc. (ZTS) Rating Reiterated by Stifel Nicolaus
Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating reiterated by research analysts at Stifel Nicolaus in a report released on Friday. They presently have a $65.00 price objective on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 3.67% from the company’s current price.
Other equities analysts have also recently issued reports about the stock. Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets cut shares of Zoetis from an “outperform” rating to a “market perform” rating and upped their price objective for the stock from $64.00 to $65.00 in a research report on Tuesday, June 13th. They noted that the move was a valuation call. Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Monday, August 14th. Jefferies Group LLC upped their price objective on shares of Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Finally, CL King assumed coverage on shares of Zoetis in a research report on Friday, May 26th. They set a “buy” rating and a $71.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $65.44.
Shares of Zoetis (NYSE:ZTS) opened at 62.70 on Friday. The company has a market capitalization of $30.67 billion, a PE ratio of 35.44 and a beta of 1.02. The firm’s 50-day moving average is $61.77 and its 200 day moving average is $58.63. Zoetis has a 52 week low of $46.86 and a 52 week high of $63.85.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.53. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.49 EPS. On average, analysts anticipate that Zoetis will post $2.34 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/01/zoetis-inc-zts-rating-reiterated-by-stifel-nicolaus.html.
Several large investors have recently bought and sold shares of ZTS. CGOV Asset Management raised its stake in Zoetis by 2.7% in the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock worth $12,059,000 after buying an additional 4,405 shares in the last quarter. Shell Asset Management Co. raised its stake in Zoetis by 1.3% in the first quarter. Shell Asset Management Co. now owns 30,092 shares of the company’s stock worth $1,606,000 after buying an additional 382 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in Zoetis by 46,440.1% in the first quarter. Canada Pension Plan Investment Board now owns 143,809 shares of the company’s stock worth $7,675,000 after buying an additional 143,500 shares in the last quarter. Jennison Associates LLC raised its stake in Zoetis by 6.0% in the first quarter. Jennison Associates LLC now owns 2,069,363 shares of the company’s stock worth $110,442,000 after buying an additional 116,644 shares in the last quarter. Finally, Advisor Partners LLC raised its stake in Zoetis by 26.8% in the first quarter. Advisor Partners LLC now owns 9,292 shares of the company’s stock worth $496,000 after buying an additional 1,965 shares in the last quarter. 93.31% of the stock is currently owned by institutional investors.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.